



Published on NAVADHI Market Research (<https://www.navadhi.com>)

[Home](#) > Global Antidiabetics Pharmaceutical Market Forecast 2023

Global Antidiabetics Pharmaceutical Market Forecast 2023



Publication ID:

NAV0619006

Publication Date:

June 07, 2019

Pages:

316

Countries:

[Global](#) [1]

Publication License Type *

Single User License (PDF), \$2,000.00

Enterprise License (PDF), \$3,000.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart

Add to wish list



Global antidiabetics pharmaceutical market is expected to grow in near future as aging and growing population, rising income levels, and emerging medical conditions and increase of lifestyle diseases help increase the demand for diabetes treatment.

Global antidiabetics pharmaceutical market is expected to be worth USD 56.18 billion by 2023.

As per NAVADHI Market Research, global antidiabetics pharmaceutical market will be worth USD 56.18 billion by 2023. The growth in this market is predicted on the basis of various factors like market drivers, current and upcoming trends, current growth pattern, and market challenges.

As per Diabetes Atlas 8th edition 2017, International Diabetes Federation, there are around 425 million people in the world who are living with diabetes, with Type 2 diabetes accounting for 90 – 95 percent of all cases. This number is expected to increase to 629 million people by 2045.

This growth in antidiabetics pharmaceutical market is fueled by the growing and ageing population in key markets. As per World Population Prospects by United Nations, the worldwide population is likely to cross 9.3 billion by 2050 and around 21% of this population is expected to be aged 60 and above. Apart from ageing and rising population the improvements in purchasing power and access to quality healthcare and pharmaceuticals to poor and middle-class families worldwide also is driving the growth of global antidiabetics pharmaceutical industry. Another aspect which is leading this growth is rising focus of antidiabetics pharmaceuticals companies to tap the obesity market as done by Novo Nordisk via its obesity treatment drug Saxenda®. Innovations in advanced biologics, nucleic acid therapeutics, cell therapies and bioelectronics & implantables has attracted investments in the industry which is fueling this growth. Also, no competition for generic manufacturers for insulin which is mostly controlled by Eli Lilly, Novo Nordisk and Sanofi has helped the market grow in revenue terms.

On the other hand, adoption of cost control policies along with tightening of rules by governments in key markets are expected to impact the growth prospect of the global antidiabetics pharmaceutical industry. In U.S. lawmakers have grilled pharma executives over higher insulin prices. This prompted Eli Lilly to introduce Lispro, a generic alternative to its insulin drug Humalog since lawmakers in their hearing had used Humalog's rising price as example during the hearing. Antidiabetics pharmaceutical companies are forced to reduce their research and development (R&D) spending and resort to huge layoffs to offset the decreasing margins on diabetes related drugs. In April 2019, Sanofi announced a new round of layoffs beginning in June 2019 to its primary care and diabetes sales teams after its insulin product sales dropped 13.8% on the year in 2018. Eli Lilly has experienced similar revenue pressure, reporting in 2018 that despite Humalog's list price growing 52% over five years, the drug's net price actually slipped 8%. It forced Eli Lilly to restructure itself in 2017 resulting in 3,500 layoffs.

Navadhi has provided detailed company profiles including their position in Global pharmaceuticals market value chain, financial performance analysis, product wise business strategy, competitive landscape and SWOT analysis for 10 key players in Global antidiabetics pharmaceutical market namely: Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck & Co. Inc, Boehringer Ingelheim, AstraZeneca PLC, Johnson & Johnson, Merck KGaA, Bayer and Takeda Pharmaceutical Company Limited.

Scope of the Global Antidiabetics Pharmaceutical Market Forecast 2023 Report

1. This report provides detailed information about Global antidiabetics pharmaceutical market including future market forecasts till 2023.
2. This report identifies the need for focusing on global antidiabetics pharmaceutical market.
3. The report identifies the growth drivers and inhibitors for global antidiabetics pharmaceutical market.
4. The report identifies various risks associated with global antidiabetics pharmaceutical market.
5. This report has detailed profiles top 10 key players in Global antidiabetics pharmaceutical market covering their business strategy, financial performance, future forecasts and SWOT analysis.
6. This report provides competitive landscape among top 10 key companies in Global antidiabetics pharmaceutical market.
7. This report provides Porter's Five Forces analysis for Global antidiabetics pharmaceutical market.
8. This report provides SWOT (strengths, weakness, opportunities and threats) analysis for Global antidiabetics pharmaceutical market.
9. This report provides information about current and future trends for Global antidiabetics pharmaceutical market.

1. Executive Summary

Scope of the Global Antidiabetics Pharmaceutical Market Forecast 2023 Report
Research Methodology

2. Introduction of Pharmaceuticals Industry

Key Product Terms Used in Pharmaceuticals Industry

Pharmaceuticals

Innovative Drugs

Orphan Drugs

Generic Drugs

Commodity Generic Drugs

Branded Generic Drugs

Biologics

Biosimilars

Over-the-counter (OTC) Drugs

Active Pharmaceutical Ingredients (APIs)

Excipients

Research and Development (R&D) Phases of Pharmaceuticals Industry

Industry-Wise Research and Development (R&D) Investment

Phase Wise Research and Development (R&D) Investment in Pharmaceuticals Industry

Global Pharmaceuticals Industry Value Chain Analysis

3. Need for Global Antidiabetics Market

Rising & Ageing Global Population

Increasing Income Levels of Poor & Middle-Class Families

4. Forecast for Global Antidiabetics Pharmaceutical Market 2023

4.1 Therapy Area-Wise Forecast for Global Pharmaceuticals Market 2018-2023

4.1.1 Forecast for Global Antidiabetics Pharmaceutical Market 2018-2023

5. Growth Drivers and Inhibitors for Global Antidiabetics Pharmaceutical Market

6. Risks Associated with Global Antidiabetics Pharmaceutical Market

- 6.1 Risk of Patent Expiry and Loss of Intellectual Property Protection
- 6.2 Risk of Commercial Success of New Products
- 6.3 Risk of Failed Research and Development Effort
- 6.4 Risk of Drug Price Controls
- 6.5 Risk of Failure to Comply with New Laws and Regulations
- 6.6 Risk of Quality Control During Complex Manufacturing Process
- 6.7 Risk of Cyber-Attacks and Data Breach
- 6.8 Risk of Volatile Currency Exchange Rates and Interest Rates
- 6.9 Risk of Unstable Global Political and Economic Conditions

7. Industry Associations Related to Global Pharmaceuticals Market

- 7.1 European Federation of Pharmaceutical Industries and Associations (EFPIA)
- 7.2 International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
- 7.3 Pharmaceutical Research and Manufacturers of America (PhRMA)
- 7.4 Association of the British Pharmaceutical Industry (ABPI)
- 7.5 Japan Pharmaceutical Manufacturers Association (JPMA)
- 7.6 Indian Drug Manufacturers' Association (IDMA)

8. Profile of Key Players in Global Antidiabetics Pharmaceutical Market

8.1 Novo Nordisk A/S

- 8.1.1 Company Profile
- 8.1.2 Novo Nordisk A/S in Pharmaceuticals Manufacturing Value Chain
- 8.1.3 Novo Nordisk A/S: Financial Performance
 - 8.1.3.1 Novo Nordisk A/S: Overall Revenue FY 2013-FY 2019 (in USD billion)
 - 8.1.3.2 Novo Nordisk A/S: Geography-Wise Revenue FY 2018 (in USD billion)
 - 8.1.3.3 Novo Nordisk A/S: Therapy Area-Wise Revenue FY 2018 (in USD billion)
- 8.1.4 Novo Nordisk A/S: Business Strategy
 - 8.1.4.1 Product Level Strategy
- 8.1.5 SWOT Analysis of Novo Nordisk A/S
 - Strengths
 - Weaknesses
 - Opportunities
 - Threats

8.2 Boehringer Ingelheim GmbH

- 8.2.1 Company Profile
- 8.2.2 Boehringer Ingelheim GmbH in Global Pharmaceuticals Manufacturing Value Chain
- 8.2.3 Boehringer Ingelheim GmbH: Financial Performance
 - 8.2.3.1 Boehringer Ingelheim GmbH: Overall Revenue FY 2013-FY 2019 (in USD billion)
 - 8.2.3.2 Boehringer Ingelheim GmbH: Geography-Wise Revenue FY 2018 (in USD billion)
 - 8.2.3.3 Boehringer Ingelheim GmbH: Division-Wise Revenue FY 2018 (in USD billion)
- 8.2.4 Boehringer Ingelheim: Business Strategy
 - 8.2.4.1 Product Level Strategy
- 8.2.5 SWOT Analysis of Boehringer Ingelheim GmbH
 - Strengths
 - Weaknesses
 - Opportunities

Threats

8.3 Johnson & Johnson

8.3.1 Company Profile

8.3.2 Johnson & Johnson in Global Pharmaceuticals Manufacturing Value Chain

8.3.3 Johnson & Johnson Financial Performance

8.3.3.1 Johnson & Johnson: Overall Revenue FY 2013-FY 2019 (in USD billion)

8.3.3.2 Johnson & Johnson: Division-Wise Revenue FY 2018 (in USD billion)

8.3.3.3 Johnson & Johnson: Geography-Wise Revenue FY 2018 (in USD billion)

8.3.3.4 Johnson & Johnson: Therapy Area-Wise Revenue FY 2018 (in USD billion)

8.3.4 Johnson & Johnson: Business Strategy

8.3.4.1 Product Level Business Strategy

8.3.5 Johnson & Johnson's Pharmaceutical Division Growth Drivers

8.3.6 SWOT Analysis of Johnson & Johnson

Strengths

Weaknesses

Opportunities

Threats

8.4 AstraZeneca PLC

8.4.1 Company Profile

8.4.2 AstraZeneca PLC in Global Pharmaceuticals Manufacturing Value Chain

8.4.3 AstraZeneca PLC: Financial Performance

8.4.3.1 AstraZeneca PLC: Overall Revenue FY 2013-FY 2019 (in USD billion)

8.4.3.2 AstraZeneca PLC: Geography-Wise Revenue FY 2018 (in USD billion)

8.4.3.3 AstraZeneca PLC: Therapy Area-Wise Revenue FY 2018 (in USD billion)

8.4.4 AstraZeneca PLC: Business Strategy

8.4.4.1 Product Level Strategy

8.4.5 SWOT Analysis of AstraZeneca Plc

Strengths

Weaknesses

Opportunities

Threats

8.5 Merck KGaA

8.5.1 Company Profile

8.5.2 Merck KGaA in Global Pharmaceuticals Manufacturing Value Chain

8.5.3 Merck KGaA: Financial Performance

8.5.3.1 Merck KGaA: Overall Revenue FY 2013-FY 2019 (in USD billion)

8.5.3.2 Merck KGaA: Geography-Wise Revenue FY 2018 (in USD billion)

8.5.3.3 Merck KGaA: Division-Wise Revenue FY 2018 (in USD billion)

8.5.3.4 Merck KGaA: Therapy Area-Wise Revenue FY 2018 (in USD billion)

8.5.4 Merck KGaA: Business Strategy

8.5.4.1 Product Level Strategy

8.5.5 SWOT Analysis of Merck KGaA

Strengths

Weaknesses

Opportunities

Threats

8.6 Merck & Co., Inc.

8.6.1 Company Profile

8.6.2 Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain

8.6.3 Merck & Co., Inc.: Financial Performance

8.6.3.1 Merck & Co., Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)

- 8.6.3.2 Merck & Co., Inc.: Division-Wise Revenue FY 2018 (in USD billion)
- 8.6.3.3 Merck & Co., Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
- 8.6.3.4 Merck & Co., Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
- 8.6.4 Merck & Co., Inc.: Business Strategy

- 8.6.4.1 Product Level Strategy

- 8.6.5 SWOT Analysis of Merck & Co., Inc.

- Strengths

- Weaknesses

- Opportunities

- Threats

8.7 Takeda Pharmaceutical Company Limited

- 8.7.1 Company Profile

- 8.7.2 Takeda Pharmaceutical Company Limited in Pharma Manufacturing Value Chain

- 8.7.3 Takeda Pharmaceutical Company Limited: Financial Performance

- 8.7.3.1 Takeda Pharmaceutical Company Limited: Overall Revenue FY 2013-FY 2019 (in USD billion)

- 8.7.3.2 Takeda Pharmaceutical Company Limited: Geography-Wise Revenue FY 2018 (in USD billion)

- 8.7.3.3 Takeda Pharmaceutical Company Limited: Therapy Area-Wise Revenue FY 2018 (in USD billion)

- 8.7.4 Takeda Pharmaceutical Company Limited: Business Strategy

- 8.7.4.1 Product Level Strategy

- 8.7.5 SWOT Analysis of Takeda Pharmaceutical Company Limited

- Strengths

- Weaknesses

- Opportunities

- Threats

8.8 Sanofi S.A.

- 8.8.1 Company Profile

- 8.8.2 Sanofi S.A. in Global Pharmaceuticals Manufacturing Value Chain

- 8.8.3 Sanofi S.A.: Financial Performance

- 8.8.3.1 Sanofi S.A.: Geography-Wise Revenue

- 8.8.4 Sanofi S.A.: Business Strategy

- 8.8.4.1 Sanofi S.A. Revenue by Global Business Units (GBU's)

- 8.8.4.2 Sanofi S.A. Revenue by Global Franchise

- 8.8.5 SWOT Analysis of Sanofi S.A.

- Strengths

- Weaknesses

- Opportunities

- Threats

- 8.8.6 Sanofi's TOP 10 Blockbusters Drugs Revenue in FY 2018 (in Euro millions)

8.9 Eli Lilly and Company

- 8.9.1 Company Profile

- 8.9.2 Eli Lilly in Global Pharmaceuticals Manufacturing Value Chain

- 8.9.3 Eli Lilly: Financial Performance

- 8.9.3.1 Eli Lilly: Overall Revenue FY 2013-FY 2019 (in USD billion)

- 8.9.3.2 Eli Lilly: Geography-Wise Revenue FY 2018 (in USD billion)

- 8.9.3.3 Eli Lilly: Division-Wise Revenue FY 2018 (in USD billion)

- 8.9.3.4 Eli Lilly: Geography-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)

- 8.9.3.5 Eli Lilly: Therapy Area-Wise Revenue FY 2018 (in USD billion)

- 8.9.4 Eli Lilly: Business Strategy

- 8.9.4.1 Product Level Strategy

- 8.9.5 SWOT Analysis of Eli Lilly and Company

Strengths
Weaknesses
Opportunities
Threats

8.10 Bayer

8.10.1 Company Profile
8.10.2 Bayer in Global Pharmaceuticals Manufacturing Value Chain
8.10.3 Bayer: Financial Performance
8.10.3.1 Bayer: Overall Revenue FY 2013-FY 2019 (in Euro billion)
8.10.3.2 Bayer: Division-Wise Revenue FY 2018 (in Euro billion)
8.10.3.3 Bayer: Geography-Wise Revenue FY 2018 (in Euro billion)
8.10.3.4 Bayer: Best Selling Pharmaceutical Products Revenue FY 2018 (in Euro billion)
8.10.3.5 Bayer: Best Selling Consumer Health Products Revenue FY 2018 (in Euro billion)
8.10.3.6 Bayer: Crop Science Segment-Wise Revenue FY 2018 (in Euro billion)
8.10.3.7 Bayer: Best Selling Animal Health Products Revenue FY 2018 (in Euro billion)
8.10.4 Bayer AG: Business Strategy
8.10.4.1 Product Level Strategy
8.10.5 SWOT Analysis of Bayer AG

Strengths
Weaknesses
Opportunities
Threats

9. Competitive Landscape in Global Antidiabetics Pharmaceutical Market

9.1 Competitive Landscape Among Top 10 Antidiabetics Companies by Antidiabetics Revenue
9.2 Competitive Landscape Among Top 10 Antidiabetics Companies by Overall Revenue
9.3 Competitive Landscape Among Top 10 Antidiabetics Companies by Global Pharmaceuticals Revenue
9.4 Competitive Landscape Among Top 10 Antidiabetics Companies by United States Revenue
9.5 Competitive Landscape Among Top 10 Antidiabetics Companies by Research and Development (R&D) Expenditure
9.6 Competitive Landscape Among Top 10 Antidiabetics Companies by Earning Per Share (EPS)
9.7 Competitive Landscape Among Top 10 Antidiabetics Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA)
9.8 Competitive Landscape Among Top 10 Antidiabetics Companies by Overall Revenue Forecast
9.9 Competitive Landscape Among Top 10 Antidiabetics Companies by Top 3 Product Revenues

10. Analysis of Global Antidiabetics Pharmaceutical Market

10.1 Porter's Five Forces Analysis of Global Antidiabetics Market
10.2 SWOT Analysis of Global Antidiabetics Pharmaceutical Market

Strengths
Weaknesses
Opportunities
Threats

11. Current and Future Trends in Global Antidiabetics Pharmaceutical Market

List of Exhibits
Notes
Company Information

List of Exhibits

- Exhibit 2.1 Research and Development Phases of Pharmaceuticals Industry
- Exhibit 2.2 Industry-Wise Research and Development Investment in Comparison to Net Sales (in %)
- Exhibit 2.3 Phase-Wise Research and Development Investment in Pharmaceuticals Industry
- Exhibit 2.4 Global Pharmaceuticals Industry Value Chain Analysis
- Exhibit 3.1 Country-Wise Population Forecast 2016-2023 (in millions)
- Exhibit 3.2 Country-Wise Purchasing Power Parity Based Per Capita GDP Forecast 2016-2023 (in USD)
- Exhibit 4.1 Therapy Area-wise Market Share in Global Pharmaceuticals Market in 2017 (in %)
- Exhibit 4.2 Forecast for Global Antidiabetics Pharmaceutical Market 2018-2023 (in USD billion)
- Exhibit 5.1 Growth Drivers and Inhibitors for Global Antidiabetics Pharmaceutical Market
- Exhibit 6.1 Country-Wise Drug Price Control Policies in Global Pharmaceuticals Market
- Exhibit 7.1 Key Information of EFPIA
- Exhibit 7.2 Contact details of EFPIA
- Exhibit 7.3 List of EFPIA Members
- Exhibit 7.4 Key Information of IFPMA
- Exhibit 7.5 Contact details of IFPMA
- Exhibit 7.6 List of IFPMA Members
- Exhibit 7.7 Key Information of PhRMA
- Exhibit 7.8 Contact details of PhRMA
- Exhibit 7.9 List of PhRMA Members
- Exhibit 7.10 Key information of ABPI
- Exhibit 7.11 Contact details of ABPI
- Exhibit 7.12 List of ABPI Members
- Exhibit 7.13 Key Information of JPMA
- Exhibit 7.13 Key Information of JPMA
- Exhibit 7.15 List of JPMA Members
- Exhibit 7.16 Key information of IDMA
- Exhibit 7.17 Contact details of IDMA
- Exhibit 8.1 Key Information of Novo Nordisk A/S
- Exhibit 8.2 Contact information of Novo Nordisk A/S
- Exhibit 8.3 Novo Nordisk A/S in Pharmaceuticals Manufacturing Value Chain
- Exhibit 8.4 Revenue of Novo Nordisk A/S FY 2013-FY 2019 (in USD billion)
- Exhibit 8.5 Revenue Growth of Novo Nordisk A/S FY 2014-FY 2019 (in %)
- Exhibit 8.6 Geography-Wise Revenue of Novo Nordisk A/S in FY 2018 (in USD billion)
- Exhibit 8.7 United States Revenue of Novo Nordisk A/S FY 2016-FY 2018 (in USD billion)
- Exhibit 8.8 United States Revenue Growth of Novo Nordisk A/S FY 2017-FY 2018 (in %)
- Exhibit 8.9 Rest of North America Revenue of Novo Nordisk A/S FY 2016-FY 2018 (in USD billion)
- Exhibit 8.10 Rest of North America Revenue Growth of Novo Nordisk A/S FY 2017-FY 2018 (in %)
- Exhibit 8.11 Europe Revenue of Novo Nordisk A/S FY 2016-FY 2018 (in USD billion)
- Exhibit 8.12 Europe Revenue Growth of Novo Nordisk A/S FY 2017-FY 2018 (in %)
- Exhibit 8.13 AAMEO (Africa, Asia, Middle East and Oceania) Revenue of Novo Nordisk A/S FY 2016-FY 2018 (in USD billion)
- Exhibit 8.14 AAMEO (Africa, Asia, Middle East and Oceania) Revenue Growth of Novo Nordisk A/S FY 2017-FY 2018 (in %)
- Exhibit 8.15 China Revenue of Novo Nordisk A/S FY 2016-FY 2018 (in USD billion)
- Exhibit 8.16 China Revenue Growth of Novo Nordisk A/S FY 2017-FY 2018 (in %)
- Exhibit 8.17 Japan and Korea Revenue of Novo Nordisk A/S FY 2016-FY 2018 (in USD billion)
- Exhibit 8.18 Japan and Korea Revenue Growth of Novo Nordisk A/S FY 2017-FY 2018 (in %)
- Exhibit 8.19 Latin America Revenue of Novo Nordisk A/S FY 2016-FY 2018 (in USD billion)
- Exhibit 8.20 Latin America Revenue Growth of Novo Nordisk A/S FY 2017-FY 2018 (in %)

Exhibit 8.21 Therapy Area-Wise Revenue of Novo Nordisk A/S in FY 2018 (in USD billion)

Exhibit 8.22 Segment-Wise, Therapy and Geography Area-Wise Revenue of Novo Nordisk A/S FY 2018 (in USD billion)

Exhibit 8.23 SWOT Analysis of Novo Nordisk A/S

Exhibit 8.24 Key Information of Boehringer Ingelheim

Exhibit 8.25 Contact Information of Boehringer Ingelheim

Exhibit 8.26 Boehringer Ingelheim GmbH in Pharmaceuticals Manufacturing Value Chain

Exhibit 8.27 Revenue of Boehringer Ingelheim FY 2013-FY 2019 (in USD billion)

Exhibit 8.28 Revenue Growth of Boehringer Ingelheim FY 2014-FY 2019 (in %)

Exhibit 8.29 Geography-Wise Revenue of Boehringer Ingelheim in FY 2018 (in USD billion)

Exhibit 8.30 United States Revenue of Boehringer Ingelheim FY 2013-FY 2018 (in USD billion)

Exhibit 8.31 United States Revenue Growth of Boehringer Ingelheim FY 2014-FY 2018 (in %)

Exhibit 8.32 Germany Revenue of Boehringer Ingelheim FY 2013-FY 2018 (in USD billion)

Exhibit 8.33 Germany Revenue Growth of Boehringer Ingelheim FY 2014-FY 2018 (in %)

Exhibit 8.34 Japan Revenue of Boehringer Ingelheim FY 2013-FY 2018 (in USD billion)

Exhibit 8.35 Japan Revenue Growth of Boehringer Ingelheim FY 2014-FY 2018 (in %)

Exhibit 8.36 Division-Wise Revenue of Boehringer Ingelheim in FY 2018 (in USD billion)

Exhibit 8.37 Pharmaceuticals Division Revenue of Boehringer Ingelheim FY 2013- FY 2018 (in USD billion)

Exhibit 8.38 Animal Division Revenue of Boehringer Ingelheim FY 2013- FY 2018 (in USD billion)

Exhibit 8.39 Biopharmaceuticals Division Revenue of Boehringer Ingelheim FY 2013- FY 2018 (in USD billion)

Exhibit 8.40 Division and Therapy Area-Wise Revenue of Boehringer Ingelheim FY 2018 (in USD billion)

Exhibit 8.41 SWOT Analysis of Boehringer Ingelheim GmbH

Exhibit 8.42 Key Information of Johnson & Johnson

Exhibit 8.43 Contact information of Johnson & Johnson

Exhibit 8.44 Johnson & Johnson in Pharmaceuticals Manufacturing Value Chain

Exhibit 8.45 Revenue of Johnson & Johnson FY 2013- FY 2019 (in USD billion)

Exhibit 8.46 Revenue Growth of Johnson & Johnson FY 2014- FY 2019 (in %)

Exhibit 8.47 Division-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)

Exhibit 8.48 Consumer Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)

Exhibit 8.49 Pharmaceuticals Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)

Exhibit 8.50 Medical Devices Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)

Exhibit 8.51 Geography-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)

Exhibit 8.52 Therapy Area-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)

Exhibit 8.53 Therapy and Geography Area-Wise Revenue of Johnson & Johnson FY 2018 (in USD billion)

Exhibit 8.54 SWOT Analysis of Johnson & Johnson

Exhibit 8.55 Key Information of AstraZeneca PLC

Exhibit 8.56 Contact Information of AstraZeneca PLC

Exhibit 8.57 AstraZeneca PLC in Pharmaceuticals Manufacturing Value Chain

Exhibit 8.58 Revenue of AstraZeneca PLC FY 2013-FY 2019 (in USD billion)

Exhibit 8.59 Revenue Growth of AstraZeneca PLC FY 2014-FY 2019 (in %)

Exhibit 8.60 Geography-Wise Revenue of AstraZeneca PLC in FY 2018 (in USD billion)

Exhibit 8.61 United States Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)

Exhibit 8.62 United States Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)

Exhibit 8.63 China Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)

Exhibit 8.64 China Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)

Exhibit 8.65 United Kingdom Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)

Exhibit 8.66 United Kingdom Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)

Exhibit 8.67 France Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)

Exhibit 8.68 France Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)

Exhibit 8.69 Germany Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)

Exhibit 8.70 Germany Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)

Exhibit 8.71 Italy Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)

Exhibit 8.72 Italy Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)

Exhibit 8.73 Spain Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)

Exhibit 8.74 Spain Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)

Exhibit 8.75 Sweden Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)

Exhibit 8.76 Sweden Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)

Exhibit 8.77 Rest of Europe Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)

Exhibit 8.78 Rest of Europe Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)

Exhibit 8.79 Rest of Europe Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)

Exhibit 8.80 Canada Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)

Exhibit 8.81 Rest of Americas Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)

Exhibit 8.82 Rest of Americas Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)

Exhibit 8.83 Australia Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)

Exhibit 8.84 Australia Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)

Exhibit 8.85 Japan Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)

Exhibit 8.86 Japan Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)

Exhibit 8.87 Rest of Asia, Africa & Australia Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)

Exhibit 8.88 Rest of Asia, Africa & Australia Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)

Exhibit 8.89 Therapy Area-Wise Revenue of AstraZeneca PLC in FY 2018 (in USD billion)

Exhibit 8.90 Therapy and Geography Area-Wise Revenue of AstraZeneca PLC FY 2018 (in USD billion)

Exhibit 8.91 SWOT Analysis of AstraZeneca PLC

Exhibit 8.92 Key Information of Merck KGaA

Exhibit 8.93 Contact Information of Merck KGaA

Exhibit 8.94 Merck KGaA in Pharmaceuticals Manufacturing Value Chain

Exhibit 8.95 Revenue of Merck KGaA FY 2013-FY 2019 (in USD billion)

Exhibit 8.96 Revenue Growth of Merck KGaA FY 2014-FY 2019 (in %)

Exhibit 8.97 Geography-Wise Revenue of Merck KGaA in FY 2018 (in USD billion)

Exhibit 8.98 Europe Revenue of Merck KGaA FY 2013-FY 2018 (in USD billion)

Exhibit 8.99 Europe Revenue Growth of Merck KGaA FY 2014-FY 2018 (in %)

Exhibit 8.100 North America Revenue of Merck KGaA FY 2013-FY 2018 (in USD billion)

Exhibit 8.101 North America Revenue Growth of Merck KGaA FY 2014-FY 2018 (in %)

Exhibit 8.102 Asia Pacific Revenue of Merck KGaA FY 2015-FY 2018 (in USD billion)

Exhibit 8.103 Asia Pacific Revenue Growth of Merck KGaA FY 2016-FY 2018 (in %)

Exhibit 8.104 Latin America Revenue of Merck KGaA FY 2015-FY 2018 (in USD billion)

Exhibit 8.105 Latin America Revenue Growth of Merck KGaA FY 2016-FY 2018 (in %)

Exhibit 8.106 Middle East and Africa Revenue of Merck KGaA FY 2015-FY 2018 (in USD billion)

Exhibit 8.107 Middle East and Africa Revenue Growth of Merck KGaA FY 2016-FY 2018 (in %)

Exhibit 8.108 Division-Wise Revenue of Merck KGaA in FY 2018 (in USD billion)

Exhibit 8.109 Healthcare Division Revenue of Merck KGaA FY 2015- FY 2018 (in USD billion)

Exhibit 8.110 Life Science Revenue of Merck KGaA FY 2015- FY 2018 (in USD billion)

Exhibit 8.111 Performance Materials Division Revenue of Merck KGaA FY 2015- FY 2018 (in USD billion)

Exhibit 8.112 Therapy Area-Wise Revenue of Merck KGaA in FY 2018 (in USD billion)

Exhibit 8.113 Healthcare Division Revenue of Merck KGaA FY 2018 (in USD billion)

Exhibit 8.114 SWOT Analysis of Merck KGaA

Exhibit 8.115 Key Information of Merck & Co.

Exhibit 8.116 Contact Information of Merck & Co.

Exhibit 8.117 Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain

Exhibit 8.118 Revenue of Merck & Co., Inc. FY 2013- FY 2019 (in USD billion)

Exhibit 8.119 Revenue Growth of Merck & Co., Inc. FY 2014-FY 2019 (in %)

Exhibit 8.120 Division-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)

Exhibit 8.121 Pharmaceuticals Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)

Exhibit 8.122 Animal Health Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)

Exhibit 8.123 Geography-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)

Exhibit 8.124 Therapy Area-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)

Exhibit 8.125 Business Division, Therapy Area and Geography Area-Wise Revenue of Merck & Co., Inc. FY 2018 (in USD billion)

Exhibit 8.126 SWOT Analysis of Merck & Co., Inc.

Exhibit 8.127 Key Information of Takeda Pharmaceutical Company Limited

Exhibit 8.129 Takeda Pharmaceutical Company Limited in Pharmaceuticals Manufacturing Value Chain

Exhibit 8.130 Revenue of Takeda Pharmaceutical Company Limited FY 2013-FY 2019 (in USD billion)

Exhibit 8.131 Revenue Growth of Takeda Pharmaceutical Company Limited FY 2014-FY 2019 (in %)

Exhibit 8.132 Geography-Wise Revenue of Takeda Pharmaceutical Company Limited in FY 2018 (in USD billion)

Exhibit 8.133 United States Revenue of Takeda Pharmaceutical Company Limited FY 2014-FY 2018 (in USD billion)

Exhibit 8.134 United States Revenue Growth of Takeda Pharmaceutical Company Limited FY 2017-FY 2018 (in %)

Exhibit 8.135 Japan Revenue of Takeda Pharmaceutical Company Limited FY 2014-FY 2018 (in USD billion)

Exhibit 8.136 Japan Revenue Growth of Takeda Pharmaceutical Company Limited FY 2015-FY 2018 (in %)

Exhibit 8.137 Europe and Canada Revenue of Takeda Pharmaceutical Company Limited FY 2014-FY 2018 (in USD billion)

Exhibit 8.138 Europe Revenue Growth of Takeda Pharmaceutical Company Limited FY 2015-FY 2018 (in %)

Exhibit 8.139 Russia/CIS Revenue of Takeda Pharmaceutical Company Limited FY 2014-FY 2018 (in USD billion)

Exhibit 8.140 Russia/CIS Revenue Growth of Takeda Pharmaceutical Company Limited FY 2015-FY 2018 (in %)

Exhibit 8.141 Latin America Revenue of Takeda Pharmaceutical Company Limited FY 2014-FY 2018 (in USD billion)

Exhibit 8.142 Latin America Revenue Growth of Takeda Pharmaceutical Company Limited FY 2015-FY 2018 (in %)

Exhibit 8.143 Asia (Excluding Japan) Revenue of Takeda Pharmaceutical Company Limited FY 2014-FY 2018 (in USD billion)

Exhibit 8.144 Asia (Excluding Japan) Revenue Growth of Takeda Pharmaceutical Company Limited FY 2015-FY 2018 (in %)

Exhibit 8.145 Rest of World Revenue of Takeda Pharmaceutical Company Limited FY 2014-FY 2018 (in USD billion)

Exhibit 8.146 Rest of World Revenue Growth of Takeda Pharmaceutical Company Limited FY 2015-FY 2018 (in %)

Exhibit 8.147 Therapy Area-Wise Revenue of Takeda Pharmaceutical Company Limited in FY 2018 (in USD billion)

Exhibit 8.148 Therapy Area-Wise Revenue of Takeda Pharmaceutical Company Limited FY 2018 (in USD billion)

Exhibit 8.149 SWOT Analysis of Takeda Pharmaceutical Company Limited

Exhibit 8.150 Key Information of Sanofi S.A.
Exhibit 8.151 Contact Information of Sanofi S.A.
Exhibit 8.152 Sanofi S.A. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.153 Sanofi S.A. Revenue FY2014-2019 (in Euro billion)
Exhibit 8.154 Year-wise Sanofi S.A. Growth 2014-19 (in %)
Exhibit 8.155 Geography-wise Sanofi S.A. Revenue Share FY 2018 (in %)
Exhibit 8.156 Geography-wise Sanofi S.A. Revenue FY 2017-2018 (in Euro million)
Exhibit 8.157 Global Business Units (GBU's)-wise Sanofi S.A. Revenue FY 2018 (in %)
Exhibit 8.158 Global Business Units (GBU's)-wise Sanofi S.A. Revenue FY 2017-2018 (in Euro million)
Exhibit 8.159 Global Franchise-wise Sanofi S.A. Revenue FY 2018 (in %)
Exhibit 8.160 Global Franchise-wise Sanofi S.A. Revenue FY 2017-2018 (in Euro million)
Exhibit 8.161 Sanofi S.A. Speciality Care Franchise Revenue FY 2018 (in %)
Exhibit 8.162 Sanofi S.A. Speciality Care Franchise Revenue FY 2015-2018 (in Euro million)
Exhibit 8.163 Sanofi S.A. Diabetes and Cardiovascular (DCV) Franchise Revenue FY 2015-2018 (in Euro million)
Exhibit 8.164 Sanofi S.A. Established Rx Products Franchise Revenue FY 2015-2018 (in Euro million)
Exhibit 8.165 Sanofi S.A. Consumer Healthcare (CHC) Franchise Revenue FY 2015-2018 (in Euro million)
Exhibit 8.166 Sanofi S.A. Generic Franchise Revenue FY 2015-2018 (in Euro million)
Exhibit 8.167 Sanofi S.A. Vaccines Franchise Revenue FY 2015-2018 (in Euro million)
Exhibit 8.168 SWOT Analysis of Sanofi S.A.
Exhibit 8.169 Top 10 Blockbuster Drug Revenue of Sanofi (in Euro millions)
Exhibit 8.170 Key information of Eli Lilly
Exhibit 8.171 Contact Information Eli Lilly
Exhibit 8.172 Eli Lilly in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.173 Revenue of Eli Lilly and Company FY 2013-FY 2019 (in USD billion)
Exhibit 8.174 Revenue Growth of Eli Lilly and Company FY 2014-FY 2019 (in %)
Exhibit 8.175 Geography-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 8.176 United States Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.177 United States Revenue Growth of Eli Lilly and Company FY 2014-FY 2018 (in %)
Exhibit 8.178 Rest of World Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.179 Rest of World Revenue Growth of Eli Lilly and Company FY 2014-FY 2018 (in %)
Exhibit 8.180 Division-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 8.181 Pharmaceuticals Division Revenue of Eli Lilly and Company FY 2013- FY 2018 (in USD billion)
Exhibit 8.182 Animal Health Division Revenue of Eli Lilly and Company FY 2013- FY 2018 (in USD billion)
Exhibit 8.183 Geography-Wise Pharmaceuticals Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 8.184 United States Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.185 Europe States Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.186 Japan Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.187 Rest of World Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.188 Therapy Area-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
Exhibit 8.189 Business Division-Wise, Therapy and Geography Area-Wise Revenue of Eli Lilly and Company FY 2018 (in USD million)
Exhibit 8.190 SWOT Analysis of Eli Lilly and Company

Exhibit 8.191 Key Information of Bayer
Exhibit 8.192 Contact Information of Bayer
Exhibit 8.193 Bayer AG in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.194 Revenue of Bayer FY 2013- FY 2019 (in Euro billion)
Exhibit 8.195 Revenue Growth of Johnson & Johnson FY 2014- FY 2019 (in %)
Exhibit 8.196 Division-Wise Revenue of Bayer in FY 2018 (in USD billion)
Exhibit 8.197 Pharmaceuticals Division Revenue of Bayer FY 2013- FY 2018 (in Euro billion)
Exhibit 8.198 Consumer Health Division Revenue of Bayer FY 2013- FY 2018 (in Euro billion)
Exhibit 8.199 Crop Science Division Revenue of Bayer FY 2013- FY 2018 (in USD billion)
Exhibit 8.200 Crop Science Division Revenue of Bayer FY 2013- FY 2018 (in USD billion)
Exhibit 8.201 Geography-Wise Revenue of Bayer in FY 2018 (in Euro billion)
Exhibit 8.202 Best Selling Pharmaceuticals Product Revenue of Bayer FY 2018 (in Euro billion)
Exhibit 8.203 Best Selling Consumer Health Product Revenue of Bayer FY 2018 (in Euro billion)
Exhibit 8.204 Crop Science Segment-Wise Revenue of Bayer FY 2018 (in Euro billion)
Exhibit 8.205 Best Selling Animal Health Product Revenue of Bayer FY 2018 (in Euro billion)
Exhibit 8.206 Bayer's Research and Development Projects (Phase II) as of January 31, 2019
Exhibit 8.207 Bayer's Research and Development Projects (Phase III) as of January 31, 2019
Exhibit 8.208 Bayer's Main Products Submitted for Approval as of January 31, 2019
Exhibit 8.209 SWOT Analysis of Bayer AG
Exhibit 9.1 Competitive Landscape Among Top 10 Antidiabetics Companies by Antidiabetics Revenue for FY2018 (in USD billion)
Exhibit 9.2 Competitive Landscape Among Top 10 Antidiabetics Companies by Overall Revenue for FY2018 (in USD billion)
Exhibit 9.3 Competitive Landscape Among Top 10 Antidiabetics Companies by Global Pharmaceuticals Revenue for FY2018 (in USD billion)
Exhibit 9.4 Competitive Landscape Among Top 10 Antidiabetics Companies by United States Revenue for FY2018 (in USD billion)
Exhibit 9.5 Competitive Landscape Among Top 10 Antidiabetics Companies by Research and Development (R&D) Expenditure for FY2018 (in USD billion)
Exhibit 9.6 Competitive Landscape Among Top 10 Antidiabetics Companies by Research and Earning Per Share (EPS) and EBITDA for FY2018 (in USD)
Exhibit 9.7 Competitive Landscape Among Top 10 Antidiabetics Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) for FY2018 (in USD billion)
Exhibit 9.8 Competitive Landscape Among Top 10 Antidiabetics Companies by Overall Revenue Forecast for FY2019 (in USD billion)
Exhibit 9.9 Competitive Landscape Among Top 10 Antidiabetics Companies by Product-Wise Antidiabetics Revenue for FY2018 (in USD billion)
Exhibit 10.1 Porter's Five Forces Analysis for Global Antidiabetics Pharmaceutical Market
Exhibit 10.2 SWOT Analysis for Global Antidiabetics Pharmaceutical Market

1. **Novo Nordisk A/S**
2. **Eli Lilly and Company**
3. **Sanofi S.A.**
4. **Merck & Co. Inc**
5. **Boehringer Ingelheim**
6. **AstraZeneca PLC**
7. **Johnson & Johnson**
8. **Merck KGaA**
9. **Bayer**
10. **Takeda Pharmaceutical Company Limited**

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Enterprise license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Enterprise license fee.

Enterprise License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

About Us



Intelligence Rediscovered

NAVADHI is a market research company that helps global firms differentiate themselves, break market entry barriers, track their investments, develop business strategies and plan for future by providing actionable market research intelligence that helps them succeed.

Information

- [About Us](#)
- [Publications](#)
- [FAQs](#)
- [Privacy Policy](#)
- [Terms & Conditions](#)
- [Careers](#)
- [Press Releases](#)
- [Contact](#)

Source URL: <https://www.navadhi.com/publications/global-antidiabetics-pharmaceutical-market-forecast-2023>

Links

[1] <https://www.navadhi.com/countries/global>